Ignite Creation Date:
2024-05-06 @ 2:07 PM
Last Modification Date:
2024-10-26 @ 1:25 PM
Study NCT ID:
NCT04224493
Status:
RECRUITING
Last Update Posted:
2024-07-01
First Post:
2019-12-12
Brief Title:
A Study to Assess the Efficacy Safety Pharmacodynamics and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With RelapsedRefractory Follicular Lymphoma
Sponsor:
Epizyme Inc
Organization:
Ipsen
Organization Data
Organization:
Ipsen
Class:
INDUSTRY
Study ID:
EZH-302
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Epizyme Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None